SCHEMBL17251702

SCHEMBL17251702

C/C=C\c1c(-c2nc3cccc(-c4cc(OC)c(OC)c(OC)c4)c3[nH]2)n[nH]c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 5/20 0.38
▸ CDK4 P11802 3/20 0.38
▸ CCNA2 P20248 3/20 0.38
▸ CCND1 P24385 3/20 0.38
▸ CDK2 P24941 3/20 0.38
▸ CCND3 P30281 3/20 0.38
▸ RPS6KA2 Q15349 1/20 0.37
▸ PDE4C Q08493 3/20 0.36
▸ CHEK1 O14757 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ AMY1A P0DUB6 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ JAK2 O60674 2/20 0.34
▸ JAK1 P23458 2/20 0.34
▸ TYK2 P29597 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18562032 0.78 CDK2 (0.56) BRD4CDK4CCNA2CCND1CDK2
SCHEMBL17251750 0.76 MAPT (0.50) BRD4PDE4CKDM4ETSHRACHE
SCHEMBL17251704 0.75 PARP1 (0.49) BRD4CDK2TP53MAPT
SCHEMBL17251741 0.67 PDE4C (0.40) BRD4PDE4CKDM4ETP53MAPT
SCHEMBL17251703 0.65 BRD4 (0.38) BRD4RPS6KA2PDE4CKDM4EMAPT
SCHEMBL17251722 0.63 CDK2 (0.53) BRD4CDK4CCNA2CCND1CDK2
SCHEMBL28116659 0.63 BRD4 (0.43) BRD4CHEK1KDM4EPOLBTSHR
SCHEMBL28116286 0.63 MAPT (0.43) BRD4KDM4EAMY1ATP53MAPT
SCHEMBL28116302 0.62 CHEK2 (0.42) BRD4KDM4EPOLBTP53MAPT
SCHEMBL28116663 0.62 KDM4E (0.47) CDK4CCND1KDM4ETP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015171628-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2015-11-12 — — WO disclosed
Send feedback